Corynebacterium Microorganism with Enhanced L-Arginine Productivity and Production Method
Summary
USPTO granted patent US12595461B2 to DAESANG CORPORATION for a Corynebacterium mutant strain with enhanced L-arginine or L-citrulline productivity. The strain has enhanced activity of acetylglutamate kinase involved in the L-arginine biosynthesis pathway. Inventors are Mi Ryu, Sun Jun Yoon, In Pyo Hong, and Seok Hyun Park. The patent covers 3 claims.
What changed
USPTO issued patent US12595461B2 to DAESANG CORPORATION for a genetically modified Corynebacterium sp. mutant strain with increased L-arginine or L-citrulline productivity. The mutant strain achieves enhanced yields compared to parent strains through improved acetylglutamate kinase activity in the L-arginine biosynthesis pathway.
This patent grant confers exclusive IP rights to DAESANG CORPORATION for the modified microorganism and methods of using it for amino acid production. Other companies in the biotechnology and fermentation industries should consider potential licensing needs before developing similar L-arginine or L-citrulline production methods using Corynebacterium strains.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Microorganism of Corynebacterium genus having enhanced L-arginine or L-citrulline productivity and a method for producing L-arginine or L-citrulline using the same
Grant US12595461B2 Kind: B2 Apr 07, 2026
Assignee
DAESANG CORPORATION
Inventors
Mi Ryu, Sun Jun Yoon, In Pyo Hong, Seok Hyun Park
Abstract
The present disclosure relates to a Corynebacterium sp. mutant strain having increased L-arginine or L-citrulline productivity and a method of producing L-arginine or L-citrulline using the same. The Corynebacterium sp. mutant strain has enhanced activity of acetylglutamate kinase involved in the L-arginine biosynthesis pathway, and thus is capable of producing L-arginine or L-citrulline in an increased yield compared to a parent strain.
CPC Classifications
C12N 1/205 C12N 9/1217 C12N 15/77 C12N 1/20 C12R 2001/15 C12P 13/10 C12Y 207/02008
Filing Date
2022-10-04
Application No.
17937828
Claims
3
Related changes
Get daily alerts for ChangeBridge: Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Biotech (C12N) publishes new changes.